Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 50-57

  Fischetti, Carmela ^a,b,c   Camarda, Valeria ^a,b   Rizzi, Anna ^a,b   Pelà, Michela ^d   Trapella, Claudio ^d   Guerrini, Remo ^d   McDonald, John ^c   Lambert, David G ^c   Salvadori, Severo ^c   Regoli, Domenico ^a,b   Calo', Girolamo ^a,b  

^a Neuroscience Center   (Italy)

^b National Institute of Neuroscience   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Calcium mobilization; Compound 24; Mouse tail withdrawal assay; N OFQ sensitive tissues; Nociceptin orphanin FQ; NOP receptor

Indexed keywords

1 BENZYL N [3 [SPIROISOBENZOFURAN 1(3H), 4' PIPERIDIN 1 YL]PROPYL]PYRROLIDINE 2 CARBOXAMIDE; CALCIUM; DELTA OPIATE RECEPTOR; ENDOMORPHIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONE; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; OPIATE AGONIST; OPIATE RECEPTOR; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CELL MEMBRANE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ELECTROSTIMULATION; FEMALE; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; MUSCLE TWITCH; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; VAS DEFERENS;

ANIMALS; BEHAVIOR, ANIMAL; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; ELECTRIC STIMULATION; GENE EXPRESSION REGULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LIGANDS; LYSINE; MALE; MICE; PEPTIDES; RECEPTORS, OPIOID; SULFUR ISOTOPES;

EID: 67349192597     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.054     Document Type: Article

References (50)

1. Bigoni R., Giuliani S., Calo G., Rizzi A., Guerrini R., Salvadori S., Regoli D., and Maggi C.A. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn-Schmiedebergs Arch. Pharmacol. 359 (1999) 160-167
2. Bigoni R., Calo G., Rizzi A., Guerrini R., De Risi C., Hashimoto Y., Hashiba E., Lambert D.G., and Regoli D. In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn-Schmiedebergs Arch. Pharmacol. 361 (2000) 565-568
3. Calo G., Guerrini R., Bigoni R., Rizzi A., Marzola G., Okawa H., Bianchi C., Lambert D.G., Salvadori S., and Regoli D. Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br. J. Pharmacol. 129 (2000) 1183-1193
4. Calo G., Rizzi A., Bogoni G., Neugebauer V., Salvadori S., Guerrini R., Bianchi C., and Regoli D. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur. J. Pharmacol. 311 (1996) R3-5
5. Calo G., Rizzi A., Marzola G., Guerrini R., Salvadori S., Beani L., Regoli D., and Bianchi C. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br. J. Pharmacol. 125 (1998) 373-378
6. Calo G., Rizzi A., Bigoni R., Guerrini R., Salvadori S., and Regoli D. Pharmacological profile of nociceptin/orphanin FQ receptors. Clin. Exp. Pharmacol. Physiol. 29 (2002) 223-228
7. Calo G., Rizzi A., Rizzi D., Bigoni R., Guerrini R., Marzola G., Marti M., McDonald J., Morari M., Lambert D.G., Salvadori S., and Regoli D. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol. 136 (2002) 303-311
8. Calo G., Guerrini R., Rizzi A., Salvadori S., Burmeister M., Kapusta D.R., Lambert D.G., and Regoli D. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev. 11 (2005) 97-112
9. Camarda V., Spagnol M., Song W., Vergura R., Roth A.L., Thompson J.P., Rowbotham D.J., Guerrini R., Marzola E., Salvadori S., Cavanni P., Regoli D., Douglas S.A., Lambert D.G., and Calo G. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5),DTrp(7),Dab(8)]urotensin II(4-11) (UFP-803). Br. J. Pharmacol. 147 (2006) 92-100
10. Camarda V., Fischetti C., Molinari P., Ambrosio C., Kostenis E., Regoli D., Guerrini R., Salvadori S., and Calo G. Pharmacological characterization of nociceptin/orphanin FQ receptors coupled with calcium signaling via the chimeric protein Galphaqi5. Naunyn Schmiedebergs Arch Pharmacol. 379 (2009) 599-607
11. Carvalho D., Petronilho F., Vuolo F., Machado R.A., Constantino L., Guerrini R., Calo G., Gavioli E.C., Streck E.L., and Dal-Pizzol F. The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Med. 34 (2008) 2284-2290
12. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
13. Chiou L.C., Liao Y.Y., Fan P.C., Kuo P.H., Wang C.H., Riemer C., and Prinssen E.P. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr. Drug Targets 8 (2007) 117-135
14. Depner U.B., Reinscheid R.K., Takeshima H., Brune K., and Zeilhofer H.U. Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor. Eur. J. Neurosci. 17 (2003) 2381-2387
15. Gavioli E.C., and Calo G. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn-Schmiedebergs Arch. Pharmacol. 372 (2006) 319-330
16. Gavioli E.C., Marzola G., Guerrini R., Bertorelli R., Zucchini S., De Lima T.C., Rae G.A., Salvadori S., Regoli D., and Calo G. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur. J. Neurosci. 17 (2003) 1987-1990
17. Gavioli E.C., Vaughan C.W., Marzola G., Guerrini R., Mitchell V.A., Zucchini S., De Lima T.C., Rae G.A., Salvadori S., Regoli D., and Calo G. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice. Naunyn-Schmiedebergs Arch. Pharmacol. 369 (2004) 547-553
18. Goto Y., Arai-Otsuki S., Tachibana Y., Ichikawa D., Ozaki S., Takahashi H., Iwasawa Y., Okamoto O., Okuda S., Ohta H., and Sagara T. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J. Med. Chem. 49 (2006) 847-849
19. Guerrini R., Calo G., Rizzi A., Bianchi C., Lazarus L.H., Salvadori S., Temussi P.A., and Regoli D. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. 40 (1997) 1789-1793
20. Hylden J.L., and Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 17 (1980) 313-316
21. Kenakin T. A Pharmacology Primer (2004), Elsevier Academic Press, San Diego
22. Koizumi M., Sakoori K., Midorikawa N., and Murphy N.P. The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism. Br. J. Pharmacol. 143 (2004) 53-62
23. Lambert D.G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat. Rev. Drug Discov. 7 (2008) 694-710
24. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some. methodological refinements. J. Pharmacol. Methods 16 (1986) 355-357
25. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
26. Marti M., Mela F., Guerrini R., Calo G., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. 91 (2004) 1501-1504
27. Marti M., Mela F., Veronesi C., Guerrini R., Salvadori S., Federici M., Mercuri N.B., Rizzi A., Franchi G., Beani L., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 24 (2004) 6659-6666
28. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M., Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M., and Morari M. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 25 (2005) 9591-9601
29. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 27 (2007) 1297-1307
30. McDonald J., Calo G., Guerrini R., and Lambert D.G. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies. Naunyn-Schmiedebergs Arch. Pharmacol. 367 (2003) 183-187
31. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monserrat B., Mazarguil H., Vassart G., Parmentier M., and Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
32. Nazzaro C., Rizzi A., Salvadori S., Guerrini R., Regoli D., Zeilhofer H.U., and Calo G. UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. Peptides 28 (2007) 663-669
33. Nishi M., Houtani T., Noda Y., Mamiya T., Sato K., Doi T., Kuno J., Takeshima H., Nukada T., Nabeshima T., Yamashita T., Noda T., and Sugimoto T. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J. 16 (1997) 1858-1864
34. Ozaki S., Kawamoto H., Itoh Y., Miyaji M., Azuma T., Ichikawa D., Nambu H., Iguchi T., Iwasawa Y., and Ohta H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur. J. Pharmacol. 402 (2000) 45-53
35. Redrobe J.P., Calo G., Regoli D., and Quirion R. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn-Schmiedebergs Arch. Pharmacol. 365 (2002) 164-167
36. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
37. Rizzi A., Nazzaro C., Marzola G., Zucchini S., Trapella C., Guerrini R., Zeilhofer H.U., Regoli D., and Calo G. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 124 (2006) 100-108
38. Rizzi A., Gavioli E.C., Marzola G., Spagnolo B., Zucchini S., Ciccocioppo R., Trapella C., Regoli D., and Calo G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J. Pharmacol. Exp. Ther. 321 (2007) 968-974
39. Rizzi A., Marzola G., Guerrini R., Salvadori S., Regoli D., and Calo G. Antinociceptive effects of nociceptin/orphanin FQ receptor agonists in the mouse writhing test in: Society of Neuroscience Abstract 269.215 Washington, DC, USA. November, 15-19 (2008)
40. Ruiz-Velasco V., Trapella C., Calo G., and Margas W. Pharmacology of constitutively active NOP opioid receptors heterologously expressed in rat sympathetic neurons, in: Society for Neuroscience, Abstract 533.9. Washington, DC, USA. November, 15-19 (2008)
41. Spagnolo B., Carra G., Fantin M., Fischetti C., Hebbes C., McDonald J., Barnes T.A., Rizzi A., Trapella C., Fanton G., Morari M., Lambert D.G., Regoli D., and Calo G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J. Pharmacol. Exp. Ther. 321 (2007) 961-967
42. Trapella C., Guerrini R., Piccagli L., Calo G., Carra G., Spagnolo B., Rubini S., Fanton G., Hebbes C., McDonald J., Lambert D.G., Regoli D., and Salvadori S. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg. Med. Chem. 14 (2006) 692-704
43. Ueda H., Inoue M., Takeshima H., and Iwasawa Y. Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. J. Neurosci. 20 (2000) 7640-7647
44. Vergura R., Valenti E., Hebbes C.P., Gavioli E.C., Spagnolo B., McDonald J., Lambert D.G., Balboni G., Salvadori S., Regoli D., and Calo G. Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides 27 (2006) 3322-3330
45. Viaro R., Sanchez-Pernaute R., Marti M., Trapella C., Isacson O., and Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced Parkinsonism. Neurobiol. Dis. 30 (2008) 430-438
46. Visanji N.P., de Bie R.M., Johnston T.H., McCreary A.C., Brotchie J.M., and Fox S.H. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 23 (2008) 1922-1925
47. Williams J.P., Thompson J.P., Young S.P., Gold S.J., McDonald J., Rowbotham D.J., and Lambert D.G. Nociceptin and urotensin-II concentrations in critically ill patients with sepsis. Br. J. Anaesth. 100 (2008) 810-814
48. Yan-Yu L., and Chiou L.C. Effect of compound 24, a novel nociceptin/orphanin FQ (NOP) receptor antagonist, on NOP receptor-mediated k+ channel activation in rat periaqueductal gray slices. Society for Neuroscience, Abstract 826.14 Washington, DC, USA. November, 15-19 (2008)
49. Zaratin P.F., Petrone G., Sbacchi M., Garnier M., Fossati C., Petrillo P., Ronzoni S., Giardina G.A., and Scheideler M.A. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9- tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J. Pharmacol. Exp. Ther. 308 (2004) 454-461
50. Zeilhofer H.U., and Calo G. Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy?. J. Pharmacol. Exp. Ther. 306 (2003) 423-429